Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
9.70
+0.60 (6.59%)
At close: Oct 24, 2025, 4:00 PM EDT
9.89
+0.19 (1.96%)
Pre-market: Oct 27, 2025, 7:40 AM EDT
Kura Oncology Stock Forecast
Stock Price Forecast
The 10 analysts that cover Kura Oncology stock have a consensus rating of "Strong Buy" and an average price target of $25, which forecasts a 157.73% increase in the stock price over the next year. The lowest target is $10 and the highest is $40.
Price Target: $25 (+157.73%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kura Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 13 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $24 | Buy | Reiterates | $24 | +147.42% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +312.37% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +312.37% | Sep 30, 2025 |
| Guggenheim | Guggenheim | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Sep 4, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $28 → $24 | Buy | Maintains | $28 → $24 | +147.42% | Aug 11, 2025 |
Financial Forecast
Revenue This Year
90.86M
from 53.88M
Increased by 68.63%
Revenue Next Year
219.52M
from 90.86M
Increased by 141.59%
EPS This Year
-2.55
from -2.02
EPS Next Year
-2.63
from -2.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 171.2M | 473.8M | |||
| Avg | 90.9M | 219.5M | |||
| Low | 28.8M | 31.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 217.6% | 421.4% | |||
| Avg | 68.6% | 141.6% | |||
| Low | -46.5% | -65.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.65 | -1.03 | |||
| Avg | -2.55 | -2.63 | |||
| Low | -3.32 | -4.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.